MX355971B - Una composición farmacéutica para tratar cáncer que comprende tripsinógeno y/o quimotripsinógeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicólisis citoplásmica. - Google Patents

Una composición farmacéutica para tratar cáncer que comprende tripsinógeno y/o quimotripsinógeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicólisis citoplásmica.

Info

Publication number
MX355971B
MX355971B MX2012004610A MX2012004610A MX355971B MX 355971 B MX355971 B MX 355971B MX 2012004610 A MX2012004610 A MX 2012004610A MX 2012004610 A MX2012004610 A MX 2012004610A MX 355971 B MX355971 B MX 355971B
Authority
MX
Mexico
Prior art keywords
compound
treating cancer
active agent
chymotrypsinogen
trypsinogen
Prior art date
Application number
MX2012004610A
Other languages
English (en)
Other versions
MX2012004610A (es
Inventor
Rodney Clayton Paul
Brandt Ralf
Norman Kenyol Julian
Tosh David
Felquer Fernando
Original Assignee
Propanc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905147A external-priority patent/AU2009905147A0/en
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Publication of MX2012004610A publication Critical patent/MX2012004610A/es
Publication of MX355971B publication Critical patent/MX355971B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a el uso de tripsinógeno y quimiotripsinógeno para preparar una composición farmacéutica para el tratamiento de un tumor sólido, en donde dicha composición no contiene amilasa, y la proporción del peso de quimiotripsinógeno:tripsinógeno se encuentra en el intervalo de entre 4:1 a 8:1.
MX2012004610A 2009-10-22 2010-10-22 Una composición farmacéutica para tratar cáncer que comprende tripsinógeno y/o quimotripsinógeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicólisis citoplásmica. MX355971B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905147A AU2009905147A0 (en) 2009-10-22 Pharmaceutical Compositions
AU2010902655A AU2010902655A0 (en) 2010-06-17 Cancer Cell Regulation
PCT/AU2010/001403 WO2011047434A1 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

Publications (2)

Publication Number Publication Date
MX2012004610A MX2012004610A (es) 2012-11-12
MX355971B true MX355971B (es) 2018-05-07

Family

ID=43899732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004610A MX355971B (es) 2009-10-22 2010-10-22 Una composición farmacéutica para tratar cáncer que comprende tripsinógeno y/o quimotripsinógeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicólisis citoplásmica.

Country Status (22)

Country Link
US (4) US9636359B2 (es)
EP (2) EP2490711A4 (es)
JP (1) JP5871805B2 (es)
KR (1) KR101936439B1 (es)
CN (2) CN102639145B (es)
AU (1) AU2010310887B9 (es)
BR (1) BR112012009521B1 (es)
CA (1) CA2814958C (es)
CL (1) CL2012001019A1 (es)
DK (1) DK3095458T3 (es)
ES (1) ES2692377T3 (es)
HK (1) HK1249017A1 (es)
IL (1) IL219216A (es)
MX (1) MX355971B (es)
NZ (1) NZ599996A (es)
PE (1) PE20121709A1 (es)
PT (1) PT3095458T (es)
RU (1) RU2012120785A (es)
SG (1) SG10201406651PA (es)
TR (1) TR201815315T4 (es)
WO (1) WO2011047434A1 (es)
ZA (1) ZA201203689B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639145B (zh) 2009-10-22 2017-09-26 普罗潘克股份有限公司 包含胰蛋白酶原和/或糜蛋白酶原和选自硒化合物，类香兰素化合物和细胞质糖酵解减少剂的活性剂的用于治疗癌的药物组合物
US9833486B2 (en) * 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
CZ307195B6 (cs) 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
MX2016011897A (es) * 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
US20160106687A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
AU2016353539B2 (en) * 2015-11-12 2020-04-23 Propanc Pty Ltd Proenzyme composition
DK3407909T3 (da) 2016-01-29 2023-11-13 Propanc Pty Ltd Cancerbehandling
EP3442564B1 (en) 2016-04-12 2023-12-06 Propanc Pty Ltd Composition of proenzymes for cancer treatment
EP3517117A1 (en) 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection
WO2022261440A1 (en) * 2021-06-11 2022-12-15 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of pancreatic cancer
EP4389913A1 (en) * 2022-12-23 2024-06-26 Universität Heidelberg A pcr-elisa analogous antibody-free method for detecting a target nucleic acid in a sample

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2727107B1 (fr) * 1994-11-21 1996-12-27 Saint Gobain Vitrage Vitrage muni d'au moins une couche mince et son procede d'obtention
CZ283972B6 (cs) 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
CN1121218C (zh) * 2000-03-08 2003-09-17 台湾东洋药品工业股份有限公司 酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
CN1471925A (zh) * 2002-08-02 2004-02-04 丛繁滋 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物
KR20050098244A (ko) * 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
US20050026852A1 (en) * 2003-05-13 2005-02-03 Rustum Youcef M. Method of augmenting the antitumor activity of anticancer agents
DE10321725A1 (de) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke
CN1557482A (zh) * 2004-02-04 2004-12-29 高春平 调节免疫功能、抗肿瘤的天然营养剂
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CN101287481A (zh) * 2005-05-26 2008-10-15 科学工业研究委员会 用于治疗肝细胞癌的药物组合物
KR100740989B1 (ko) 2005-07-22 2007-07-19 넨시스(주) 구형 항염·항암효소 과립제 및 이의 제조방법
CN1944641B (zh) * 2006-10-26 2010-11-03 上海林叶生物科技有限公司 高纯度糜蛋白酶的制备方法
US9381168B2 (en) * 2007-11-09 2016-07-05 Catholic University Industry Academy Cooperation Foundation Use of capsiate or dihydrocapsidate
CN102639145B (zh) 2009-10-22 2017-09-26 普罗潘克股份有限公司 包含胰蛋白酶原和/或糜蛋白酶原和选自硒化合物，类香兰素化合物和细胞质糖酵解减少剂的活性剂的用于治疗癌的药物组合物
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů

Also Published As

Publication number Publication date
BR112012009521B1 (pt) 2021-07-13
US10350239B2 (en) 2019-07-16
PT3095458T (pt) 2018-11-09
WO2011047434A1 (en) 2011-04-28
EP3095458B1 (en) 2018-07-25
US20230137573A1 (en) 2023-05-04
HK1249017A1 (zh) 2018-10-26
KR20120128124A (ko) 2012-11-26
US20180064753A1 (en) 2018-03-08
KR101936439B1 (ko) 2019-01-08
ES2692377T3 (es) 2018-12-03
NZ599996A (en) 2014-06-27
CN102639145B (zh) 2017-09-26
CA2814958C (en) 2023-09-26
US9636359B2 (en) 2017-05-02
EP2490711A1 (en) 2012-08-29
AU2010310887B2 (en) 2015-09-03
AU2010310887A1 (en) 2012-06-07
CN107625957A (zh) 2018-01-26
SG10201406651PA (en) 2014-11-27
CL2012001019A1 (es) 2013-07-12
US20190388463A1 (en) 2019-12-26
JP2013508307A (ja) 2013-03-07
IL219216A (en) 2017-03-30
CN102639145A (zh) 2012-08-15
DK3095458T3 (en) 2018-11-19
BR112012009521A2 (pt) 2016-05-17
CA2814958A1 (en) 2011-04-28
JP5871805B2 (ja) 2016-03-01
MX2012004610A (es) 2012-11-12
PE20121709A1 (es) 2012-12-17
TR201815315T4 (tr) 2018-11-21
EP2490711A4 (en) 2013-04-03
IL219216A0 (en) 2012-06-28
AU2010310887B9 (en) 2015-10-08
ZA201203689B (en) 2013-02-27
EP3095458A1 (en) 2016-11-23
US20120251516A1 (en) 2012-10-04
CN107625957B (zh) 2021-06-15
RU2012120785A (ru) 2013-11-27

Similar Documents

Publication Publication Date Title
MX355971B (es) Una composición farmacéutica para tratar cáncer que comprende tripsinógeno y/o quimotripsinógeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicólisis citoplásmica.
PH12014501639A1 (en) Pharmaceutical compositions and methods
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
TR201907783T4 (tr) Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
EA201390031A1 (ru) МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
NZ703148A (en) Modified factor x polypeptides and uses thereof
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MX2009011970A (es) Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
HK1106534A1 (en) Proteasome inhibitors and methods of using the same
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2008125116A3 (en) Upar inhibition
MX2013006188A (es) Agentes de generacion de imagenes pet de apoptosis.
WO2012064146A3 (ko) Ｇｋｎ １을 함유하는 항암용 조성물
EA201590796A1 (ru) Фибринолитические композиции, включающие бромелаин и наттокиназу, для предотвращения и лечения флеботромботических состояний
MY166634A (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
WO2009126804A3 (en) Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
WO2014062811A3 (en) METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2
EP3581660A3 (en) Niche targeting of quiescent cancer stem cells

Legal Events

Date Code Title Description
FG Grant or registration